Mei Xiao

created a new article

1 w

Immunogenicity of biologic agents | #immunogenicity

Immunogenicity of biologic agents

Immunogenicity of biologic agents

All biological agents are immunogenic and many pathways affect their bioavailability, including patient-specific factors, disease-specific characteristics, and genetic background.

Like

Comment

Share

created a new article

1 w

Immunogenicity Testing of Medicilon | #immunogenicity Testing

Immunogenicity Testing of Medicilon

Immunogenicity Testing of Medicilon

Immunogenicity testing is focused on the detection and characterization of anti-drug antibodies (ADAs) and the determination whether these ADAs are neutralizing antibodies(NABs), as NABs may affect the pharmacokinetics (PK) of the drug. It is clear however that animal studies are no

Like

Comment

Share

created a new article

1 w

Discovery of Rapidly Adapting Antibody Opens Door for Universal Flu Vaccines | #flu Vaccines

Discovery of Rapidly Adapting Antibody Opens Door for Universal Flu Vaccines

Discovery of Rapidly Adapting Antibody Opens Door for Universal Flu Vaccines

With flu season rapidly advancing, attention will shift to what novel ideas scientists have developed to protect public health. Now, it would seem investigators at the Dana-Farber Cancer Institute are looking to take the lead in this critical discussion because they have recently published

Like

Comment

Share

created a new article

1 w

Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation | #abm-1310

Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients

Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients

Shanghai, China/San Diego,USA - August 2, 2023, ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM).

Like

Comment

Share

created a new article

1 w

Enzyme Catalysis | #enzyme Catalysis

Enzyme Catalysis

Enzyme Catalysis

As a CRO that advocates green drug research and development, Medicilon has always been committed to promoting the green upgrading of pharmaceutical processes through technological innovation. Medicilon has already used enzymes in process research and development, and relying on its strong

Like

Comment

Share

Load more posts

Female
posts 98

02/02/04
Working at Medicilon
Living in United States
https://www.medicilon.com/

Albums

(0)

(7)

(186)

Likes

(0)

Groups

(0)